---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059756"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:33:21.263255+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics Q3 2023 net loss $24.5M; cash $214.7M funds into 2025

## Summary
- Net loss of $24.5M ($0.55 per share) vs $26.1M ($0.66) in Q3 2022.
- Revenue of $3.3M from Acadia license/services; cash runway to end of 2025.
- STK-001 Phase 1/2a results plus OLE data expected Q1 2024; then regulatory meeting for Phase 3 design.
- STK-002 Phase 1 study (OSPREY) for ADOA to start in UK early 2024.

## SEC filing metadata
- accession: 0000950170-23-059756
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017023059756/0000950170-23-059756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017023059756/stok-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059756
- JSON: https://secwatch.observer/filing/0000950170-23-059756.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059756.txt

## Key facts
- Earnings Releases
  Stoke Therapeutics, Inc. reported three months ended September 30, 2023 results: revenue $3.3 million, net income -$24.5 million, EPS -$0.55 per share.
  - Period: three months ended September 30, 2023
  - Revenue: $3.3 million
  - Net income: -$24.5 million
  - EPS: -$0.55 per share
  - Result: reported results
  source text: Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended September 30, 2023, was $3.3 million, compared to $2.9 million for the same period in 2022. • Net loss for the three months ended September 30, 2023, was $24.5 million, or $0.55 per share, compared to $26.1 million, or $0.66 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000095017023059756/0000950170-23-059756-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.